Company intelligence / Profile preview
BlossomHill Therapeutics
San Diego, California, United Statesbhtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Currently conducting two Phase 1/2 clinical trials: SOLARA study for BH-30643 in EGFR/HER2-mutated NSCLC (first cohort dosed in January 2025) and a trial for BH-30236 in relapsed/refractory AML and HR-MDS. BH-30643 has demonstrated promising PK and safety profile in preclinical studies, including good cardio-safety.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on BlossomHill Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BlossomHill Therapeutics.